Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response

SIMPLE SUMMARY: The use of biologic agents in the treatment of immune adverse events (irAEs) due to immune checkpoint inhibitors has been an attractive option but there are limited data on their impact on tumor progression. This study is one of the largest retrospective cohorts that evaluated the pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Parvathareddy, Vishnupriyadevi, Selamet, Umut, Sen, Aditi A., Mamlouk, Omar, Song, Juhee, Page, Valda D., Abdelrahim, Maen, Diab, Adi, Abdel-Wahab, Noha, Abudayyeh, Ala
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649345/
https://www.ncbi.nlm.nih.gov/pubmed/37958355
http://dx.doi.org/10.3390/cancers15215181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649345/
https://www.ncbi.nlm.nih.gov/pubmed/37958355
http://dx.doi.org/10.3390/cancers15215181

Ejemplares similares